Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

Core Insights - The ENVET-BE clinical utility study confirms the effectiveness of EsoGuard as a non-invasive triage tool that significantly increases the positive yield of invasive upper endoscopy for detecting esophageal precancer [1][2] - EsoGuard testing demonstrated a 2.4-fold increase in the overall positive diagnostic yield for Barrett's Esophagus (BE) compared to the expected yield from screening EGD alone, with nearly three-fold higher yield in patients meeting ACG screening criteria [2] Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc., focusing on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer [3] - The company's EsoGuard Esophageal DNA Test is the first and only commercially available tool designed for early detection of esophageal precancer in at-risk patients [3]